Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing.  The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading

Removing Bias from HEOR: Standardizing the Costs of Adverse Events

What are the total costs of prescribing a particular drug? At its core, all health economics and outcomes research (HEOR) studies are designed to answer this fundamental question. And it is this answer that helps to remove barriers to market… Continue Reading

21st Century Cures and Off-Label Promotion Benefit HEOR and Drug Safety

As my writing for the AdverseEvents Blog can attest, I’m in favor of data transparency. In my view, no organization should have monopolistic control over important information that limits the ability for healthcare decision makers to perform unbiased, objective comparative… Continue Reading

WHEN 1+1=3: HOW ELECTRONIC HEALTH RECORDS AND CLAIMS CAN BE USED SYNERGISTICALLY

Sponsored blog posting by DaVita Clinical Research. 1. Combining Drug Development with Real-World Data Analytics DaVita Clinical Research® (DCR®), a specialty full-service contract research organization, recently merged with HealthCare Partners Clinical Research to further expand its clinical research and data… Continue Reading